Incyte’s Retifanlimab Tests US FDA’s Tolerance For Low Response Rates In Accelerated Approval
US FDA advisory committee votes 13-4 to wait for Phase III data in anal cancer, expected in 2025.
You may also be interested in...
Accelerated Approval Is For Patients, Not Sponsors – US FDA’s Pazdur
Biotech sponsors understandably discuss accelerated approval as an important consideration in development plans. But the head of the US FDA oncology program has a reminder for them: the pathway is intended to serve patients – not drug companies.
Rx For Immuno-Oncology Excess? Top US FDA Cancer Officials Take On Development ‘Wild West’
Rapid, uncoordinated growth has turned the PD-1/L1 inhibitor pipeline into a global stampede, FDA’s Pazdur and Beaver say. Solutions like a unified submission pathway and coordinated trial design pose challenges requiring international cooperation among governments and industry alike.
Gilead’s First-In-Class Drug For Aggressive Breast Cancer On Track For EU Approval
EU reviewers have recommended five new medicines and a pneumococcal vaccine for EU-wide approval. New uses of several approved medicines have also drawn the thumbs up, while the sponsor of a cancer drug has withdrawn its product from the review process.